{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T11:22:30Z","timestamp":1794568950735,"version":"4.9.1"},"reference-count":202,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1038\/s41584-025-01318-6","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:44:43Z","timestamp":1762508683000},"page":"703-718","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Cutaneous lupus erythematosus \u2014 from pathogenesis to targeted therapy"],"prefix":"10.1038","volume":"21","author":[{"given":"Benjamin","family":"Klein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7115-9113","authenticated-orcid":false,"given":"Allison C.","family":"Billi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6543-7014","authenticated-orcid":false,"given":"Lisa","family":"Abernathy-Close","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4006-8945","authenticated-orcid":false,"given":"J. Michelle","family":"Kahlenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,7]]},"reference":[{"key":"1318_CR1","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1097\/00005792-199303000-00005","volume":"72","author":"R Cervera","year":"1993","unstructured":"Cervera, R. et al. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus. Medicine 72, 113\u2013124 (1993).","journal-title":"Medicine"},{"key":"1318_CR2","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/S0190-9622(81)80261-7","volume":"4","author":"JN Gilliam","year":"1981","unstructured":"Gilliam, J. N. & Sontheimer, R. D. Distinctive cutaneous subsets in the spectrum of lupus erythematosus. J. Am. Acad. Dermatol. 4, 471\u2013475 (1981).","journal-title":"J. Am. Acad. Dermatol."},{"key":"1318_CR3","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jaut.2014.01.021","volume":"48\u201349","author":"A Kuhn","year":"2014","unstructured":"Kuhn, A. & Landmann, A. The classification and diagnosis of cutaneous lupus erythematosus. J. Autoimmun. 48\u201349, 14\u201319 (2014).","journal-title":"J. Autoimmun."},{"key":"1318_CR4","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1111\/j.1365-2133.2011.10272.x","volume":"164","author":"CM Gr\u00f6nhagen","year":"2011","unstructured":"Gr\u00f6nhagen, C. M., Fored, C. M., Granath, F. & Nyberg, F. Cutaneous lupus erythematosus and the association with systemic lupus erythematosus: a population-based cohort of 1088 patients in Sweden. Br. J. Dermatol. 164, 1335\u20131341 (2011).","journal-title":"Br. J. Dermatol."},{"key":"1318_CR5","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s40257-016-0173-9","volume":"17","author":"EZ Hejazi","year":"2016","unstructured":"Hejazi, E. Z. & Werth, V. P. Cutaneous lupus erythematosus: an update on pathogenesis, diagnosis and treatment. Am. J. Clin. Dermatol. 17, 135\u2013146 (2016).","journal-title":"Am. J. Clin. Dermatol."},{"key":"1318_CR6","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3899\/jrheum.220089","volume":"50","author":"C Stull","year":"2023","unstructured":"Stull, C., Sprow, G. & Werth, V. P. Cutaneous involvement in systemic lupus erythematosus: a review for the rheumatologist. J. Rheumatol. 50, 27\u201335 (2023).","journal-title":"J. Rheumatol."},{"key":"1318_CR7","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.jaad.2010.02.008","volume":"64","author":"R Klein","year":"2011","unstructured":"Klein, R. et al. Quality of life in cutaneous lupus erythematosus. J. Am. Acad. Dermatol. 64, 849\u2013858 (2011).","journal-title":"J. Am. Acad. Dermatol."},{"key":"1318_CR8","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/j.1365-2133.2012.11106.x","volume":"168","author":"R Vasquez","year":"2013","unstructured":"Vasquez, R. et al. A multicentre, cross-sectional study on quality of life in patients with cutaneous lupus erythematosus. Br. J. Dermatol. 168, 145\u2013153 (2013).","journal-title":"Br. J. Dermatol."},{"key":"1318_CR9","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1177\/0961203320951842","volume":"29","author":"ME Ogunsanya","year":"2020","unstructured":"Ogunsanya, M. E., Cho, S. K., Hudson, A. & Chong, B. F. Factors associated with quality of life in cutaneous lupus erythematosus using the Revised Wilson and Cleary Model. Lupus 29, 1691\u20131703 (2020).","journal-title":"Lupus"},{"key":"1318_CR10","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1016\/j.mayocp.2022.06.022","volume":"97","author":"M Hocao\u011flu","year":"2022","unstructured":"Hocao\u011flu, M. et al. Epidemiology of cutaneous lupus erythematosus among adults over four decades (1976\u20132018): a Lupus Midwest Network (LUMEN) study. Mayo Clin. Proc. 97, 2282\u20132290 (2022).","journal-title":"Mayo Clin. Proc."},{"key":"1318_CR11","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1001\/archdermatol.2009.21","volume":"145","author":"O Durosaro","year":"2009","unstructured":"Durosaro, O., Davis, M. D., Reed, K. B. & Rohlinger, A. L. Incidence of cutaneous lupus erythematosus, 1965\u20132005: a population-based study. Arch. Dermatol. 145, 249\u2013253 (2009).","journal-title":"Arch. Dermatol."},{"key":"1318_CR12","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1002\/acr.22502","volume":"67","author":"S Jarukitsopa","year":"2015","unstructured":"Jarukitsopa, S. et al. Epidemiology of systemic lupus erythematosus and cutaneous lupus erythematosus in a predominantly white population in the United States. Arthritis Care Res. 67, 817\u2013828 (2015).","journal-title":"Arthritis Care Res."},{"key":"1318_CR13","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/1346-8138.15162","volume":"47","author":"YS Baek","year":"2020","unstructured":"Baek, Y. S., Park, S. H., Baek, J., Roh, J. Y. & Kim, H. J. Cutaneous lupus erythematosus and its association with systemic lupus erythematosus: a nationwide population-based cohort study in Korea. J. Dermatol. 47, 163\u2013165 (2020).","journal-title":"J. Dermatol."},{"key":"1318_CR14","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1002\/acr.23578","volume":"71","author":"C Drenkard","year":"2019","unstructured":"Drenkard, C. et al. Racial disparities in the incidence of primary chronic cutaneous lupus erythematosus in the Southeastern US: the Georgia lupus registry. Arthritis Care Res. 71, 95\u2013103 (2019).","journal-title":"Arthritis Care Res."},{"key":"1318_CR15","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1177\/0961203316651745","volume":"25","author":"P Jarrett","year":"2016","unstructured":"Jarrett, P., Thornley, S. & Scragg, R. Ethnic differences in the epidemiology of cutaneous lupus erythematosus in New Zealand. Lupus 25, 1497\u20131502 (2016).","journal-title":"Lupus"},{"key":"1318_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.866319","volume":"13","author":"P Curtiss","year":"2022","unstructured":"Curtiss, P., Walker, A. M. & Chong, B. F. A systematic review of the progression of cutaneous lupus to systemic lupus erythematosus. Front. Immunol. 13, 866319 (2022).","journal-title":"Front. Immunol."},{"key":"1318_CR17","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1001\/jamadermatol.2013.9026","volume":"150","author":"IT Wieczorek","year":"2014","unstructured":"Wieczorek, I. T., Propert, K. J., Okawa, J. & Werth, V. P. Systemic symptoms in the progression of cutaneous to systemic lupus erythematosus. JAMA Dermatol. 150, 291\u2013296 (2014).","journal-title":"JAMA Dermatol."},{"key":"1318_CR18","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1001\/archderm.1982.01650180046015","volume":"118","author":"JP Callen","year":"1982","unstructured":"Callen, J. P. Chronic cutaneous lupus erythematosus. Clinical, laboratory, therapeutic, and prognostic examination of 62 patients. Arch. Dermatol. 118, 412\u2013416 (1982).","journal-title":"Arch. Dermatol."},{"key":"1318_CR19","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/j.1365-2133.2011.10610.x","volume":"166","author":"BF Chong","year":"2012","unstructured":"Chong, B. F., Song, J. & Olsen, N. J. Determining risk factors for developing systemic lupus erythematosus in patients with discoid lupus erythematosus. Br. J. Dermatol. 166, 29\u201335 (2012).","journal-title":"Br. J. Dermatol."},{"key":"1318_CR20","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1159\/000246716","volume":"190","author":"T Watanabe","year":"1995","unstructured":"Watanabe, T. & Tsuchida, T. Classification of lupus erythematosus based upon cutaneous manifestations. Dermatological, systemic and laboratory findings in 191 patients. Dermatology 190, 277\u2013283 (1995).","journal-title":"Dermatology"},{"key":"1318_CR21","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.jaad.2012.09.024","volume":"68","author":"BC B\u00f6ckle","year":"2013","unstructured":"B\u00f6ckle, B. C., Stanarevic, G. & Sepp, N. T. Detection of Ro\/SS-A antibodies in lupus erythematosus: what does it mean for the dermatologist? J. Am. Acad. Dermatol. 68, 385\u2013394 (2013).","journal-title":"J. Am. Acad. Dermatol."},{"key":"1318_CR22","doi-asserted-by":"publisher","first-page":"370","DOI":"10.2340\/00015555-0473","volume":"88","author":"K Popovic","year":"2008","unstructured":"Popovic, K., Wahren-Herlenius, M. & Nyberg, F. Clinical follow-up of 102 anti-Ro\/SSA-positive patients with dermatological manifestations. Acta Derm. Venereol. 88, 370\u2013375 (2008).","journal-title":"Acta Derm. Venereol."},{"key":"1318_CR23","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1002\/art.1780400928","volume":"40","author":"MC Hochberg","year":"1997","unstructured":"Hochberg, M. C. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 40, 1725 (1997).","journal-title":"Arthritis Rheum."},{"key":"1318_CR24","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.jaad.2022.09.028","volume":"88","author":"L Fredeau","year":"2023","unstructured":"Fredeau, L. et al. Risk factors of progression from discoid lupus to severe systemic lupus erythematosus: a registry-based cohort study of 164 patients. J. Am. Acad. Dermatol. 88, 551\u2013559 (2023).","journal-title":"J. Am. Acad. Dermatol."},{"key":"1318_CR25","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1001\/archderm.1988.01670060015008","volume":"124","author":"TB Fitzpatrick","year":"1988","unstructured":"Fitzpatrick, T. B. The validity and practicality of sun-reactive skin types I through VI. Arch. Dermatol. 124, 869\u2013871 (1988).","journal-title":"Arch. Dermatol."},{"key":"1318_CR26","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1016\/j.jaad.2024.01.041","volume":"90","author":"C Masseran","year":"2024","unstructured":"Masseran, C. et al. Comparison of patients with isolated cutaneous lupus erythematosus versus systemic lupus erythematosus with cutaneous lupus erythematosus as the sole clinical feature: a monocentric study of 149 patients. J. Am. Acad. Dermatol. 90, 1210\u20131217 (2024).","journal-title":"J. Am. Acad. Dermatol."},{"key":"1318_CR27","doi-asserted-by":"publisher","first-page":"305","DOI":"10.2340\/0001555577305308","volume":"77","author":"B Tebbe","year":"1997","unstructured":"Tebbe, B. et al. Markers in cutaneous lupus erythematosus indicating systemic involvement. A multicenter study on 296 patients. Acta Derm. Venereol. 77, 305\u2013308 (1997).","journal-title":"Acta Derm. Venereol."},{"key":"1318_CR28","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1146\/annurev.immunol.23.021704.115843","volume":"23","author":"AN Theofilopoulos","year":"2005","unstructured":"Theofilopoulos, A. N., Baccala, R., Beutler, B. & Kono, D. H. Type I interferons (\u03b1\/\u03b2) in immunity and autoimmunity. Annu. Rev. Immunol. 23, 307\u2013335 (2005).","journal-title":"Annu. Rev. Immunol."},{"key":"1318_CR29","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1001\/jamadermatol.2025.1697","volume":"161","author":"S Henning","year":"2025","unstructured":"Henning, S. et al. Nonlesional skin and blood interferon scores among patients with a history of cutaneous lupus. JAMA Dermatol. 161, 822\u2013827\u00a0(2025).","journal-title":"JAMA Dermatol."},{"key":"1318_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19918-z","volume":"11","author":"A Psarras","year":"2020","unstructured":"Psarras, A. et al. Functionally impaired plasmacytoid dendritic cells and non-haematopoietic sources of type I interferon characterize human autoimmunity. Nat. Commun. 11, 6149 (2020).","journal-title":"Nat. Commun."},{"key":"1318_CR31","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1186\/s13075-019-2034-4","volume":"21","author":"WM Lambers","year":"2019","unstructured":"Lambers, W. M. et al. Interferon score is increased in incomplete systemic lupus erythematosus and correlates with myxovirus-resistance protein A in blood and skin. Arthritis Res. Ther. 21, 260 (2019).","journal-title":"Arthritis Res. Ther."},{"key":"1318_CR32","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.ado1710","volume":"10","author":"B Klein","year":"2025","unstructured":"Klein, B. et al. Epidermal ZBP1 stabilizes mitochondrial Z-DNA to drive UV-induced IFN signaling in autoimmune photosensitivity. Sci. Immunol. 10, eado1710 (2025).","journal-title":"Sci. Immunol."},{"key":"1318_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114607","volume":"43","author":"MB Reynolds","year":"2024","unstructured":"Reynolds, M. B. et al. Type I interferon governs immunometabolic checkpoints that coordinate inflammation during Staphylococcal infection. Cell Rep. 43, 114607 (2024).","journal-title":"Cell Rep."},{"key":"1318_CR34","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1002\/path.1721","volume":"205","author":"J Wenzel","year":"2005","unstructured":"Wenzel, J. et al. Enhanced type I interferon signalling promotes Th1-biased inflammation in cutaneous lupus erythematosus. J. Pathol. 205, 435\u2013442 (2005).","journal-title":"J. Pathol."},{"key":"1318_CR35","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1136\/annrheumdis-2018-213197","volume":"77","author":"MK Sarkar","year":"2018","unstructured":"Sarkar, M. K. et al. Photosensitivity and type I IFN responses in cutaneous lupus are driven by epidermal-derived interferon kappa. Ann. Rheum. Dis. 77, 1653\u20131664 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"1318_CR36","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jdcr.2024.11.014","volume":"55","author":"B Abdelmalik","year":"2025","unstructured":"Abdelmalik, B., Svoboda, S., Gurnani, P. & Motaparthi, K. Successful treatment of recalcitrant cutaneous lupus erythematosus with anifrolumab in patients without systemic lupus erythematosus. JAAD Case Rep. 55, 57\u201361 (2025).","journal-title":"JAAD Case Rep."},{"key":"1318_CR37","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1093\/bjd\/ljad089","volume":"189","author":"LM Carter","year":"2023","unstructured":"Carter, L. M., Wigston, Z., Laws, P. & Vital, E. M. Rapid efficacy of anifrolumab across multiple subtypes of recalcitrant cutaneous lupus erythematosus parallels changes in discrete subsets of blood transcriptomic and cellular biomarkers. Br. J. Dermatol. 189, 210\u2013218 (2023).","journal-title":"Br. J. Dermatol."},{"key":"1318_CR38","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1002\/art.39962","volume":"69","author":"R Furie","year":"2017","unstructured":"Furie, R. et al. Anifrolumab, an anti-interferon-\u03b1 receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus. Arthritis Rheumatol. 69, 376\u2013386 (2017).","journal-title":"Arthritis Rheumatol."},{"key":"1318_CR39","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.142067","volume":"5","author":"Y Jiang","year":"2020","unstructured":"Jiang, Y. et al. Cytokinocytes: the diverse contribution of keratinocytes to immune responses in skin. JCI Insight 5, e142067 (2020).","journal-title":"JCI Insight"},{"key":"1318_CR40","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1002\/art.42235","volume":"74","author":"J Patel","year":"2022","unstructured":"Patel, J. et al. Multidimensional immune profiling of cutaneous lupus erythematosus in vivo stratified by patient response to antimalarials. Arthritis Rheumatol. 74, 1687\u20131698 (2022).","journal-title":"Arthritis Rheumatol."},{"key":"1318_CR41","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1016\/j.jid.2023.10.039","volume":"144","author":"T Vazquez","year":"2024","unstructured":"Vazquez, T. et al. Plasmacytoid dendritic cells are not major producers of type 1 IFN in cutaneous lupus: an in-depth immunoprofile of subacute and discoid lupus. J. Invest. Dermatol. 144, 1262\u20131272.e7 (2024).","journal-title":"J. Invest. Dermatol."},{"key":"1318_CR42","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abn2263","volume":"14","author":"AC Billi","year":"2022","unstructured":"Billi, A. C. et al. Nonlesional lupus skin contributes to inflammatory education of myeloid cells and primes for cutaneous inflammation. Sci. Transl. Med. 14, eabn2263 (2022).","journal-title":"Sci. Transl. Med."},{"key":"1318_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaut.2012.07.005","volume":"40","author":"A Hansel","year":"2013","unstructured":"Hansel, A. et al. Human 6-sulfo LacNAc (slan) dendritic cells have molecular and functional features of an important pro-inflammatory cell type in lupus erythematosus. J. Autoimmun. 40, 1\u20138 (2013).","journal-title":"J. Autoimmun."},{"key":"1318_CR44","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.jid.2018.07.041","volume":"139","author":"M Zeidi","year":"2019","unstructured":"Zeidi, M., Kim, H. J. & Werth, V. P. Increased myeloid dendritic cells and TNF-\u03b1 expression predicts poor response to hydroxychloroquine in cutaneous lupus erythematosus. J. Invest. Dermatol. 139, 324\u2013332 (2019).","journal-title":"J. Invest. Dermatol."},{"key":"1318_CR45","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20221156","volume":"220","author":"J Maelfait","year":"2023","unstructured":"Maelfait, J. & Rehwinkel, J. The Z-nucleic acid sensor ZBP1 in health and disease. J. Exp. Med. 220, e20221156 (2023).","journal-title":"J. Exp. Med."},{"key":"1318_CR46","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/nature09907","volume":"472","author":"JW Schoggins","year":"2011","unstructured":"Schoggins, J. W. et al. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 472, 481\u2013485 (2011).","journal-title":"Nature"},{"key":"1318_CR47","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.4049\/jimmunol.1402066","volume":"194","author":"F Ma","year":"2015","unstructured":"Ma, F. et al. Positive feedback regulation of type I IFN production by the IFN-inducible DNA sensor cGAS. J. Immunol. 194, 1545\u20131554 (2015).","journal-title":"J. Immunol."},{"key":"1318_CR48","doi-asserted-by":"publisher","first-page":"3013","DOI":"10.1016\/j.cell.2023.05.039","volume":"186","author":"Y Lei","year":"2023","unstructured":"Lei, Y. et al. Cooperative sensing of mitochondrial DNA by ZBP1 and cGAS promotes cardiotoxicity. Cell 186, 3013\u20133032.e22\u00a0(2023).","journal-title":"Cell"},{"key":"1318_CR49","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/s41577-021-00633-9","volume":"22","author":"YJ Crow","year":"2022","unstructured":"Crow, Y. J. & Stetson, D. B. The type I interferonopathies: 10 years on. Nat. Rev. Immunol. 22, 471\u2013483 (2022).","journal-title":"Nat. Rev. Immunol."},{"key":"1318_CR50","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41584-024-01184-8","volume":"21","author":"R Goldbach-Mansky","year":"2025","unstructured":"Goldbach-Mansky, R., Alehashemi, S. & de Jesus, A. A. Emerging concepts and treatments in autoinflammatory interferonopathies and monogenic systemic lupus erythematosus. Nat. Rev. Rheumatol. 21, 22\u201345 (2025).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1318_CR51","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1001\/jamadermatol.2014.3438","volume":"151","author":"C Gunther","year":"2015","unstructured":"Gunther, C., Berndt, N., Wolf, C. & Lee-Kirsch, M. A. Familial chilblain lupus due to a novel mutation in the exonuclease III domain of 3\u2019 repair exonuclease 1 (TREX1). JAMA Dermatol. 151, 426\u2013431 (2015).","journal-title":"JAMA Dermatol."},{"key":"1318_CR52","doi-asserted-by":"publisher","first-page":"e179","DOI":"10.1016\/j.jaad.2013.04.020","volume":"69","author":"C Gunther","year":"2013","unstructured":"Gunther, C., Hillebrand, M., Brunk, J. & Lee-Kirsch, M. A. Systemic involvement in TREX1-associated familial chilblain lupus. J. Am. Acad. Dermatol. 69, e179\u2013e181 (2013).","journal-title":"J. Am. Acad. Dermatol."},{"key":"1318_CR53","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1159\/000222430","volume":"219","author":"C Gunther","year":"2009","unstructured":"Gunther, C., Meurer, M., Stein, A., Viehweg, A. & Lee-Kirsch, M. A. Familial chilblain lupus \u2014 a monogenic form of cutaneous lupus erythematosus due to a heterozygous mutation in TREX1. Dermatology 219, 162\u2013166 (2009).","journal-title":"Dermatology"},{"key":"1318_CR54","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s00109-007-0199-9","volume":"85","author":"MA Lee-Kirsch","year":"2007","unstructured":"Lee-Kirsch, M. A. et al. A mutation in TREX1 that impairs susceptibility to granzyme A-mediated cell death underlies familial chilblain lupus. J. Mol. Med. 85, 531\u2013537 (2007).","journal-title":"J. Mol. Med."},{"key":"1318_CR55","doi-asserted-by":"publisher","first-page":"5993","DOI":"10.4049\/jimmunol.1400737","volume":"192","author":"A Ablasser","year":"2014","unstructured":"Ablasser, A. et al. TREX1 deficiency triggers cell-autonomous immunity in a cGAS-dependent manner. J. Immunol. 192, 5993\u20135997 (2014).","journal-title":"J. Immunol."},{"key":"1318_CR56","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1038\/ni.1941","volume":"11","author":"N Yan","year":"2010","unstructured":"Yan, N., Regalado-Magdos, A. D., Stiggelbout, B., Lee-Kirsch, M. A. & Lieberman, J. The cytosolic exonuclease TREX1 inhibits the innate immune response to human immunodeficiency virus type 1. Nat. Immunol. 11, 1005\u20131013 (2010).","journal-title":"Nat. Immunol."},{"key":"1318_CR57","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.jid.2021.04.037","volume":"142","author":"N Berndt","year":"2022","unstructured":"Berndt, N. et al. Photosensitivity and cGAS-dependent IFN-1 activation in patients with lupus and TREX1 deficiency. J. Investig. Dermatol. 142, 633\u2013640.e6 (2022).","journal-title":"J. Investig. Dermatol."},{"key":"1318_CR58","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.916011","volume":"9","author":"HW Chen","year":"2022","unstructured":"Chen, H. W., Barber, G. & Chong, B. F. The genetic landscape of cutaneous lupus erythematosus. Front. Med. 9, 916011 (2022).","journal-title":"Front. Med."},{"key":"1318_CR59","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.ard.2025.01.011","volume":"84","author":"Y Zeng","year":"2025","unstructured":"Zeng, Y. et al. Somatic gain-of-function mutation in TLR7 causes early-onset systemic lupus erythematosus. Ann. Rheum. Dis. 84, 442\u2013450 (2025).","journal-title":"Ann. Rheum. Dis."},{"key":"1318_CR60","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adi9769","volume":"9","author":"C Wolf","year":"2024","unstructured":"Wolf, C. et al. UNC93B1 variants underlie TLR7-dependent autoimmunity. Sci. Immunol. 9, eadi9769 (2024).","journal-title":"Sci. Immunol."},{"key":"1318_CR61","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20232066","volume":"221","author":"C David","year":"2024","unstructured":"David, C. et al. Gain-of-function human UNC93B1 variants cause systemic lupus erythematosus and chilblain lupus. J. Exp. Med. 221, e20232066 (2024).","journal-title":"J. Exp. Med."},{"key":"1318_CR62","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1111\/exd.12708","volume":"24","author":"M Kunz","year":"2015","unstructured":"Kunz, M. et al. Genome-wide association study identifies new susceptibility loci for cutaneous lupus erythematosus. Exp. Dermatol. 24, 510\u2013515 (2015).","journal-title":"Exp. Dermatol."},{"key":"1318_CR63","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0014212","volume":"5","author":"TM J\u00e4rvinen","year":"2010","unstructured":"J\u00e4rvinen, T. M. et al. Polymorphisms of the ITGAM gene confer higher risk of discoid cutaneous than of systemic lupus erythematosus. PLoS ONE\u00a05, e14212 (2010).","journal-title":"PLoS ONE"},{"key":"1318_CR64","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1136\/ard.2011.154104","volume":"70","author":"E Sanchez","year":"2011","unstructured":"Sanchez, E. et al. Phenotypic associations of genetic susceptibility loci in systemic lupus erythematosus. Ann. Rheum. Dis. 70, 1752\u20131757 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"1318_CR65","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.gene.2013.06.074","volume":"527","author":"AM da Silva Fonseca","year":"2013","unstructured":"da Silva Fonseca, A. M. et al. Polymorphisms in STK17A gene are associated with systemic lupus erythematosus and its clinical manifestations. Gene 527, 435\u2013439 (2013).","journal-title":"Gene"},{"key":"1318_CR66","doi-asserted-by":"publisher","first-page":"706825","DOI":"10.1155\/2010\/706825","volume":"2010","author":"IT Harley","year":"2010","unstructured":"Harley, I. T. et al. The role of genetic variation near interferon-kappa in systemic lupus erythematosus. J. Biomed. Biotechnol. 2010, 706825 (2010).","journal-title":"J. Biomed. Biotechnol."},{"key":"1318_CR67","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2147\/TCRM.S10145","volume":"7","author":"A Reich","year":"2011","unstructured":"Reich, A., Marcinow, K. & Bialynicki-Birula, R. The lupus band test in systemic lupus erythematosus patients. Ther. Clin. Risk Manag. 7, 27\u201332 (2011).","journal-title":"Ther. Clin. Risk Manag."},{"key":"1318_CR68","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jid.2016.09.008","volume":"137","author":"JN Stannard","year":"2017","unstructured":"Stannard, J. N. et al. Lupus skin is primed for IL-6 inflammatory responses through a keratinocyte-mediated autocrine type I interferon loop. J. Invest. Dermatol. 137, 115\u2013122 (2017).","journal-title":"J. Invest. Dermatol."},{"key":"1318_CR69","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1002\/art.42460","volume":"75","author":"GA Hile","year":"2023","unstructured":"Hile, G. A. et al. The Hippo pathway regulates photosensitivity in lupus skin. Arthritis Rheumatol. 75, 1216\u20131228\u00a0(2023).","journal-title":"Arthritis Rheumatol."},{"key":"1318_CR70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11926-024-01168-3","volume":"27","author":"B Klein","year":"2024","unstructured":"Klein, B., Nguyen, N. T. K., Moallemian, R. & Kahlenberg, J. M. Keratinocytes \u2014 amplifiers of immune responses in systemic lupus erythematosus. Curr. Rheumatol. Rep. 27, 1 (2024).","journal-title":"Curr. Rheumatol. Rep."},{"key":"1318_CR71","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.4049\/jimmunol.1800650","volume":"202","author":"LC Tsoi","year":"2019","unstructured":"Tsoi, L. C. et al. Hypersensitive IFN responses in lupus keratinocytes reveal key mechanistic determinants in cutaneous lupus. J. Immunol. 202, 2121\u20132130 (2019).","journal-title":"J. Immunol."},{"key":"1318_CR72","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41423-024-01240-z","volume":"22","author":"J Tian","year":"2025","unstructured":"Tian, J. et al. Dysregulation in keratinocytes drives systemic lupus erythematosus onset. Cell. Mol. Immunol. 22, 83\u201396 (2025).","journal-title":"Cell. Mol. Immunol."},{"key":"1318_CR73","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/s41423-024-01254-7","volume":"22","author":"B Klein","year":"2025","unstructured":"Klein, B., Billi, A. C. & Kahlenberg, J. M. Increasing evidence for the pathogenic role of keratinocytes in lupus. Cell Mol. Immunol. 22, 333\u2013335\u00a0(2025).","journal-title":"Cell Mol. Immunol."},{"key":"1318_CR74","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jaad.2013.03.015","volume":"69","author":"K Foering","year":"2013","unstructured":"Foering, K. et al. Characterization of clinical photosensitivity in cutaneous lupus erythematosus. J. Am. Acad. Dermatol. 69, 205\u2013213 (2013).","journal-title":"J. Am. Acad. Dermatol."},{"key":"1318_CR75","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.jid.2021.05.007","volume":"142","author":"SN Estadt","year":"2022","unstructured":"Estadt, S. N., Maz, M. P., Musai, J. & Kahlenberg, J. M. Mechanisms of photosensitivity in autoimmunity. J. Invest. Dermatol. 142, 849\u2013856 (2022).","journal-title":"J. Invest. Dermatol."},{"key":"1318_CR76","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.939594","volume":"9","author":"B Klein","year":"2022","unstructured":"Klein, B. & Kunz, M. Current concepts of photosensitivity in cutaneous lupus erythematosus. Front. Med. 9, 939594 (2022).","journal-title":"Front. Med."},{"key":"1318_CR77","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/phpp.12018","volume":"29","author":"A Kim","year":"2013","unstructured":"Kim, A. & Chong, B. F. Photosensitivity in cutaneous lupus erythematosus. Photodermatol. Photoimmunol. Photomed. 29, 4\u201311 (2013).","journal-title":"Photodermatol. Photoimmunol. Photomed."},{"key":"1318_CR78","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1038\/jid.2011.101","volume":"131","author":"A Kuhn","year":"2011","unstructured":"Kuhn, A. et al. Photoprovocation in cutaneous lupus erythematosus: a multicenter study evaluating a standardized protocol. J. Invest. Dermatol. 131, 1622\u20131630 (2011).","journal-title":"J. Invest. Dermatol."},{"key":"1318_CR79","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1067\/mjd.2001.114589","volume":"45","author":"A Kuhn","year":"2001","unstructured":"Kuhn, A. et al. Phototesting in lupus erythematosus: a 15-year experience. J. Am. Acad. Dermatol. 45, 86\u201395 (2001).","journal-title":"J. Am. Acad. Dermatol."},{"key":"1318_CR80","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1002\/art.21658","volume":"54","author":"A Kuhn","year":"2006","unstructured":"Kuhn, A. et al. Accumulation of apoptotic cells in the epidermis of patients with cutaneous lupus erythematosus after ultraviolet irradiation. Arthritis Rheum. 54, 939\u2013950 (2006).","journal-title":"Arthritis Rheum."},{"key":"1318_CR81","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1384606","volume":"15","author":"SN Loftus","year":"2024","unstructured":"Loftus, S. N. et al. Interferon alpha promotes caspase-8 dependent ultraviolet light-mediated keratinocyte apoptosis via interferon regulatory factor 1. Front. Immunol. 15, 1384606 (2024).","journal-title":"Front. Immunol."},{"key":"1318_CR82","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1002\/art.21034","volume":"52","author":"S Meller","year":"2005","unstructured":"Meller, S. et al. Ultraviolet radiation-induced injury, chemokines, and leukocyte recruitment: an amplification cycle triggering cutaneous lupus erythematosus. Arthritis Rheum. 52, 1504\u20131516 (2005).","journal-title":"Arthritis Rheum."},{"key":"1318_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2019.06.002","volume":"103","author":"SJ Wolf","year":"2019","unstructured":"Wolf, S. J. et al. Ultraviolet light induces increased T cell activation in lupus-prone mice via type I IFN-dependent inhibition of T regulatory cells. J. Autoimmun. 103, 102291 (2019).","journal-title":"J. Autoimmun."},{"key":"1318_CR84","doi-asserted-by":"publisher","DOI":"10.1002\/art.43350","author":"B Klein","year":"2025","unstructured":"Klein, B. et al. Epidermal Interferon kappa drives cutaneous lupus-like lesions, photosensitivity and systemic autoimmunity in vivo. Arthritis Rheumatol. https:\/\/doi.org\/10.1002\/art.43350 (2025).","journal-title":"Arthritis Rheumatol."},{"key":"1318_CR85","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-64865-w","volume":"10","author":"S Skopelja-Gardner","year":"2020","unstructured":"Skopelja-Gardner, S. et al. The early local and systemic type I interferon responses to ultraviolet B light exposure are cGAS dependent. Sci. Rep. 10, 7908 (2020).","journal-title":"Sci. Rep."},{"key":"1318_CR86","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2019097118","volume":"118","author":"S Skopelja-Gardner","year":"2021","unstructured":"Skopelja-Gardner, S. et al. Acute skin exposure to ultraviolet light triggers neutrophil-mediated kidney inflammation. Proc. Natl Acad. Sci. USA 118, e2019097118 (2021).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1318_CR87","doi-asserted-by":"publisher","first-page":"8996","DOI":"10.1039\/C5OB01340B","volume":"13","author":"J Wang","year":"2015","unstructured":"Wang, J., Wang, S., Zhong, C., Tian, T. & Zhou, X. Novel insights into a major DNA oxidative lesion: its effects on Z-DNA stabilization. Org. Biomol. Chem. 13, 8996\u20138999 (2015).","journal-title":"Org. Biomol. Chem."},{"key":"1318_CR88","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.immuni.2013.08.004","volume":"39","author":"N Gehrke","year":"2013","unstructured":"Gehrke, N. et al. Oxidative damage of DNA confers resistance to cytosolic nuclease TREX1 degradation and potentiates STING-dependent immune sensing. Immunity 39, 482\u2013495 (2013).","journal-title":"Immunity"},{"key":"1318_CR89","doi-asserted-by":"publisher","first-page":"5740","DOI":"10.1016\/j.cell.2021.10.010","volume":"184","author":"JR Buzzo","year":"2021","unstructured":"Buzzo, J. R. et al. Z-form extracellular DNA is a structural component of the bacterial biofilm matrix. Cell 184, 5740\u20135758.e5717 (2021).","journal-title":"Cell"},{"key":"1318_CR90","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/1523-1747.ep12873930","volume":"94","author":"F Furukawa","year":"1990","unstructured":"Furukawa, F., Kashihara-Sawami, M., Lyons, M. B. & Norris, D. A. Binding of antibodies to the extractable nuclear antigens SS-A\/Ro and SS-B\/La is induced on the surface of human keratinocytes by ultraviolet light (UVL): implications for the pathogenesis of photosensitive cutaneous lupus. J. Investig. Dermatol. 94, 77\u201385 (1990).","journal-title":"J. Investig. Dermatol."},{"key":"1318_CR91","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/S0891-5849(02)00797-9","volume":"32","author":"J Saegusa","year":"2002","unstructured":"Saegusa, J. et al. Oxidative stress mediates cell surface expression of SS-A\/Ro antigen on keratinocytes. Free. Radic. Biol. Med. 32, 1006\u20131016 (2002).","journal-title":"Free. Radic. Biol. Med."},{"key":"1318_CR92","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1084\/jem.179.4.1317","volume":"179","author":"LA Casciola-Rosen","year":"1994","unstructured":"Casciola-Rosen, L. A., Anhalt, G. & Rosen, A. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J. Exp. Med. 179, 1317\u20131330 (1994).","journal-title":"J. Exp. Med."},{"key":"1318_CR93","doi-asserted-by":"publisher","first-page":"9699","DOI":"10.3390\/ijms22189699","volume":"22","author":"N Berndt","year":"2021","unstructured":"Berndt, N. et al. And yet it moves: oxidation of the nuclear autoantigen La\/SS-B is the driving force for nucleo-cytoplasmic shuttling. Int. J. Mol. Sci. 22, 9699 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"1318_CR94","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.3390\/ijms22073377","volume":"22","author":"N Berndt","year":"2021","unstructured":"Berndt, N. et al. Two be or not two be: the nuclear autoantigen La\/SS-B is able to form dimers and oligomers in a redox dependent manner. Int. J. Mol. Sci. 22, 3377 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"1318_CR95","doi-asserted-by":"publisher","first-page":"eaap9527","DOI":"10.1126\/scitranslmed.aap9527","volume":"10","author":"WD Shipman","year":"2018","unstructured":"Shipman, W. D. et al. A protective Langerhans cell-keratinocyte axis that is dysfunctional in photosensitivity. Sci. Transl. Med. 10, eaap9527 (2018).","journal-title":"Sci. Transl. Med."},{"key":"1318_CR96","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.85914","volume":"13","author":"TM Li","year":"2024","unstructured":"Li, T. M. et al. The interferon-rich skin environment regulates Langerhans cell ADAM17 to promote photosensitivity in lupus. eLife 13, e85914 (2024).","journal-title":"eLife"},{"key":"1318_CR97","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1002\/art.43108","volume":"77","author":"X Sun","year":"2025","unstructured":"Sun, X., Chao, J. L., Gerner, M. & Elkon, K. B. Induction of type I interferon-dependent activation and migration of inflammatory dendritic cells to local lymph nodes by UV light exposure. Arthritis Rheumatol. 77, 867\u2013875\u00a0(2025).","journal-title":"Arthritis Rheumatol."},{"key":"1318_CR98","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2024.103296","volume":"149","author":"MP Maz","year":"2024","unstructured":"Maz, M. P. et al. Lupus-prone NZM2328 mice exhibit enhanced UV-induced myeloid cell recruitment and activation in a type I interferon dependent manner. J. Autoimmun. 149, 103296 (2024).","journal-title":"J. Autoimmun."},{"key":"1318_CR99","doi-asserted-by":"publisher","unstructured":"Tumurkhuu, G. et al. Loss of tripartite motif-containing protein 21 and UVB-induced systemic inflammation by regulating DNA-sensing pathways. Arthritis Rheumatol. https:\/\/doi.org\/10.1002\/art.43273 (2025).","DOI":"10.1002\/art.43273"},{"key":"1318_CR100","doi-asserted-by":"publisher","DOI":"10.1172\/JCI168412","volume":"135","author":"MJ Howlader","year":"2025","unstructured":"Howlader, M. J. et al. Lymphatic dysfunction in lupus contributes to cutaneous photosensitivity and lymph node B cell responses. J. Clin. Invest. 135, e168412 (2025).","journal-title":"J. Clin. Invest."},{"key":"1318_CR101","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1177\/09612033211025095","volume":"30","author":"HY Zhou","year":"2021","unstructured":"Zhou, H. Y. et al. Systemic lupus erythematosus patients have a distinct structural and functional skin microbiota compared with controls. Lupus 30, 1553\u20131564 (2021).","journal-title":"Lupus"},{"key":"1318_CR102","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1086\/499632","volume":"193","author":"MJ Kuehnert","year":"2006","unstructured":"Kuehnert, M. J. et al. Prevalence of Staphylococcus aureus nasal colonization in the United States, 2001\u20132002. J. Infect. Dis. 193, 172\u2013179 (2006).","journal-title":"J. Infect. Dis."},{"key":"1318_CR103","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abm9811","volume":"7","author":"H Terui","year":"2022","unstructured":"Terui, H. et al. skin colonization promotes SLE-like autoimmune inflammation via neutrophil activation and the IL-23\/IL-17 axis. Sci. Immunol. 7, eabm9811 (2022).","journal-title":"Sci. Immunol."},{"key":"1318_CR104","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1093\/rheumatology\/ken196","volume":"47","author":"MJ Chen","year":"2008","unstructured":"Chen, M. J. et al. Long-term outcome and short-term survival of patients with systemic lupus erythematosus after bacteraemia episodes: 6-yr follow-up. Rheumatology 47, 1352\u20131357 (2008).","journal-title":"Rheumatology"},{"key":"1318_CR105","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/j.jid.2019.11.016","volume":"140","author":"S Sirobhushanam","year":"2020","unstructured":"Sirobhushanam, S. et al. Staphylococcus aureus colonization is increased on lupus skin lesions and is promoted by IFN-mediated barrier disruption. J. Invest. Dermatol. 140, 1066\u20131074.e4 (2020).","journal-title":"J. Invest. Dermatol."},{"key":"1318_CR106","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1186\/s13075-016-1079-x","volume":"18","author":"F Conti","year":"2016","unstructured":"Conti, F. et al. Association between Staphylococcus aureus nasal carriage and disease phenotype in patients affected by systemic lupus erythematosus. Arthritis Res. Ther. 18, 177 (2016).","journal-title":"Arthritis Res. Ther."},{"key":"1318_CR107","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2019.102391","volume":"108","author":"C Huang","year":"2020","unstructured":"Huang, C. et al. Disordered cutaneous microbiota in systemic lupus erythematosus. J. Autoimmun. 108, 102391 (2020).","journal-title":"J. Autoimmun."},{"key":"1318_CR108","unstructured":"Gul\u2019neva, M. I., Romanov, V. A. & Shilkina, N. P. Intestinal microecology in some systemic connective tissue diseases [Russian]. Zh Mikrobiol. Epidemiol. Immunobiol. 38\u201341 (2007)."},{"key":"1318_CR109","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1002\/art.43079","volume":"77","author":"L Abernathy-Close","year":"2025","unstructured":"Abernathy-Close, L. et al. Topical mupirocin treatment reduces interferon and myeloid signatures in cutaneous lupus erythematous lesions through targeting of Staphylococcus species. Arthritis Rheumatol. 77, 705\u2013715 (2025).","journal-title":"Arthritis Rheumatol."},{"key":"1318_CR110","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.4049\/jimmunol.1201097","volume":"189","author":"VR Chowdhary","year":"2012","unstructured":"Chowdhary, V. R., Tilahun, A. Y., Clark, C. R., Grande, J. P. & Rajagopalan, G. Chronic exposure to staphylococcal superantigen elicits a systemic inflammatory disease mimicking lupus. J. Immunol. 189, 2054\u20132062 (2012).","journal-title":"J. Immunol."},{"key":"1318_CR111","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1189\/jlb.4A1214-577RR","volume":"98","author":"JW Chung","year":"2015","unstructured":"Chung, J. W. et al. Superantigens produced by catheter-associated Staphylococcus aureus elicit systemic inflammatory disease in the absence of bacteremia. J. Leukoc. Biol. 98, 271\u2013281 (2015).","journal-title":"J. Leukoc. Biol."},{"key":"1318_CR112","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms2441","volume":"4","author":"T Nakatsuji","year":"2013","unstructured":"Nakatsuji, T. et al. The microbiome extends to subepidermal compartments of normal skin. Nat. Commun. 4, 1431 (2013).","journal-title":"Nat. Commun."},{"key":"1318_CR113","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1016\/j.jid.2016.05.127","volume":"136","author":"T Nakatsuji","year":"2016","unstructured":"Nakatsuji, T. et al. Staphylococcus aureus exploits epidermal barrier defects in atopic dermatitis to trigger cytokine expression. J. Invest. Dermatol. 136, 2192\u20132200 (2016).","journal-title":"J. Invest. Dermatol."},{"key":"1318_CR114","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1001\/archdermatol.2011.342","volume":"148","author":"EW Piette","year":"2012","unstructured":"Piette, E. W. et al. Impact of smoking in cutaneous lupus erythematosus. Arch. Dermatol. 148, 317\u2013322 (2012).","journal-title":"Arch. Dermatol."},{"key":"1318_CR115","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-38178-7","volume":"13","author":"K Hergesell","year":"2023","unstructured":"Hergesell, K. et al. The effect of long-term cigarette smoking on selected skin barrier proteins and lipids. Sci. Rep. 13, 11572 (2023).","journal-title":"Sci. Rep."},{"key":"1318_CR116","doi-asserted-by":"publisher","first-page":"17111","DOI":"10.1073\/pnas.1206851109","volume":"109","author":"K Biniek","year":"2012","unstructured":"Biniek, K., Levi, K. & Dauskardt, R. H. Solar UV radiation reduces the barrier function of human skin. Proc. Natl Acad. Sci. USA 109, 17111\u201317116 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1318_CR117","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1177\/0961203321995257","volume":"30","author":"N Ezeh","year":"2021","unstructured":"Ezeh, N., McKown, T., Garg, S. & Bartels, C. M. Smoking exposure in pack-years predicts cutaneous manifestations and damage in systemic lupus erythematosus. Lupus 30, 649\u2013654 (2021).","journal-title":"Lupus"},{"key":"1318_CR118","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1002\/art.20049","volume":"50","author":"KH Costenbader","year":"2004","unstructured":"Costenbader, K. H. et al. Cigarette smoking and the risk of systemic lupus erythematosus: a meta-analysis. Arthritis Rheum. 50, 849\u2013857 (2004).","journal-title":"Arthritis Rheum."},{"key":"1318_CR119","first-page":"2449","volume":"28","author":"NO Ghaussy","year":"2001","unstructured":"Ghaussy, N. O., Sibbitt, W. L. & Qualls, C. R. Cigarette smoking, alcohol consumption, and the risk of systemic lupus erythematosus: a case-control study. J. Rheumatol. 28, 2449\u20132453 (2001).","journal-title":"J. Rheumatol."},{"key":"1318_CR120","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1177\/0961203314559630","volume":"24","author":"BC B\u00f6ckle","year":"2015","unstructured":"B\u00f6ckle, B. C. & Sepp, N. T. Smoking is highly associated with discoid lupus erythematosus and lupus erythematosus tumidus: analysis of 405 patients. Lupus 24, 669\u2013674 (2015).","journal-title":"Lupus"},{"key":"1318_CR121","first-page":"1716","volume":"25","author":"P Rahman","year":"1998","unstructured":"Rahman, P., Gladman, D. D. & Urowitz, M. B. Smoking interferes with efficacy of antimalarial therapy in cutaneous lupus. J. Rheumatol. 25, 1716\u20131719 (1998).","journal-title":"J. Rheumatol."},{"key":"1318_CR122","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1067\/mjd.2000.103635","volume":"42","author":"ML Jewell","year":"2000","unstructured":"Jewell, M. L. & McCauliffe, D. P. Patients with cutaneous lupus erythematosus who smoke are less responsive to antimalarial treatment. J. Am. Acad. Dermatol. 42, 983\u2013987 (2000).","journal-title":"J. Am. Acad. Dermatol."},{"key":"1318_CR123","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.jaad.2014.12.025","volume":"72","author":"F Chasset","year":"2015","unstructured":"Chasset, F., Franc\u00e8s, C., Barete, S., Amoura, Z. & Arnaud, L. Influence of smoking on the efficacy of antimalarials in cutaneous lupus: a meta-analysis of the literature. J. Am. Acad. Dermatol. 72, 634\u2013639 (2015).","journal-title":"J. Am. Acad. Dermatol."},{"key":"1318_CR124","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1177\/09612033231183500","volume":"32","author":"HW Chen","year":"2023","unstructured":"Chen, H. W., Sprow, G., Feng, R., Werth, V. P. & Chong, B. F. Cigarette smoking is associated with decreased long-term treatment cessation of mycophenolate mofetil and methotrexate in cutaneous lupus erythematosus. Lupus 32, 1134\u20131137 (2023).","journal-title":"Lupus"},{"key":"1318_CR125","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2021-000537","volume":"8","author":"WD Raymond","year":"2021","unstructured":"Raymond, W. D., Hamdorf, M., Furfaro, M., Eilertsen, G. O. & Nossent, J. C. Smoking associates with increased BAFF and decreased interferon-\u03b3 levels in patients with systemic lupus erythematosus. Lupus Sci. Med. 8, e000537 (2021).","journal-title":"Lupus Sci. Med."},{"key":"1318_CR126","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1111\/j.1365-2133.2007.08137.x","volume":"157","author":"J Wenzel","year":"2007","unstructured":"Wenzel, J. et al. The expression pattern of interferon-inducible proteins reflects the characteristic histological distribution of infiltrating immune cells in different cutaneous lupus erythematosus subsets. Br. J. Dermatol. 157, 752\u2013757 (2007).","journal-title":"Br. J. Dermatol."},{"key":"1318_CR127","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/jid.2010.244","volume":"131","author":"S Zahn","year":"2011","unstructured":"Zahn, S. et al. Evidence for a pathophysiological role of keratinocyte-derived type III interferon (IFN\u03bb) in cutaneous lupus erythematosus. J. Investig. Dermatol. 131, 133\u2013140 (2011).","journal-title":"J. Investig. Dermatol."},{"key":"1318_CR128","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/nrrheum.2010.46","volume":"6","author":"LE Mu\u00f1oz","year":"2010","unstructured":"Mu\u00f1oz, L. E., Lauber, K., Schiller, M., Manfredi, A. A. & Herrmann, M. The role of defective clearance of apoptotic cells in systemic autoimmunity. Nat. Rev. Rheumatol. 6, 280\u2013289 (2010).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1318_CR129","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1038\/jid.2008.453","volume":"129","author":"V Oke","year":"2009","unstructured":"Oke, V. et al. High Ro52 expression in spontaneous and UV-induced cutaneous inflammation. J. Invest. Dermatol. 129, 2000\u20132010 (2009).","journal-title":"J. Invest. Dermatol."},{"key":"1318_CR130","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1136\/ard.54.11.904","volume":"54","author":"T D\u00f6rner","year":"1995","unstructured":"D\u00f6rner, T. et al. Enhanced membrane expression of the 52 kDa Ro(SS-A) and La(SS-B) antigens by human keratinocytes induced by TNF alpha. Ann. Rheum. Dis. 54, 904\u2013909 (1995).","journal-title":"Ann. Rheum. Dis."},{"key":"1318_CR131","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.166076","volume":"8","author":"AJ Little","year":"2023","unstructured":"Little, A. J. et al. HIF-1 regulates pathogenic cytotoxic T cells in lupus skin disease. JCI Insight 8, e166076 (2023).","journal-title":"JCI Insight"},{"key":"1318_CR132","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.156341","volume":"7","author":"GS Dunlap","year":"2022","unstructured":"Dunlap, G. S. et al. Single-cell transcriptomics reveals distinct effector profiles of infiltrating T cells in lupus skin and kidney. JCI Insight 7, e156341 (2022).","journal-title":"JCI Insight"},{"key":"1318_CR133","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-35209-1","volume":"13","author":"M Zheng","year":"2022","unstructured":"Zheng, M. et al. Single-cell sequencing shows cellular heterogeneity of cutaneous lesions in lupus erythematosus. Nat. Commun. 13, 7489 (2022).","journal-title":"Nat. Commun."},{"key":"1318_CR134","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2022.109172","volume":"245","author":"M Zheng","year":"2022","unstructured":"Zheng, M. et al. Single-cell transcriptome reveals immunopathological cell composition of skin lesions in subacute cutaneous lupus erythematosus. Clin. Immunol. 245, 109172 (2022).","journal-title":"Clin. Immunol."},{"key":"1318_CR135","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.ejim.2010.03.004","volume":"21","author":"C Tanasescu","year":"2010","unstructured":"Tanasescu, C. et al. IL-17 in cutaneous lupus erythematosus. Eur. J. Intern. Med. 21, 202\u2013207 (2010).","journal-title":"Eur. J. Intern. Med."},{"key":"1318_CR136","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/j.1365-2230.2010.03996.x","volume":"36","author":"SH Oh","year":"2011","unstructured":"Oh, S. H. et al. Expression of interleukin-17 is correlated with interferon-\u03b1 expression in cutaneous lesions of lupus erythematosus. Clin. Exp. Dermatol. 36, 512\u2013520 (2011).","journal-title":"Clin. Exp. Dermatol."},{"key":"1318_CR137","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/jid.2013.269","volume":"134","author":"A Jabbari","year":"2014","unstructured":"Jabbari, A. et al. Dominant Th1 and minimal Th17 skewing in discoid lupus revealed by transcriptomic comparison with psoriasis. J. Invest. Dermatol. 134, 87\u201395 (2014).","journal-title":"J. Invest. Dermatol."},{"key":"1318_CR138","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.ygeno.2014.06.003","volume":"104","author":"R Dey-Rao","year":"2014","unstructured":"Dey-Rao, R., Smith, J. R., Chow, S. & Sinha, A. A. Differential gene expression analysis in CCLE lesions provides new insights regarding the genetics basis of skin vs. systemic disease. Genomics 104, 144\u2013155 (2014).","journal-title":"Genomics"},{"key":"1318_CR139","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1136\/ard-2022-222858","volume":"81","author":"RF van Vollenhoven","year":"2022","unstructured":"van Vollenhoven, R. F. et al. Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus. Ann. Rheum. Dis. 81, 1556\u20131563 (2022).","journal-title":"Ann. Rheum. Dis."},{"key":"1318_CR140","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1038\/nri2358","volume":"8","author":"M Gilliet","year":"2008","unstructured":"Gilliet, M., Cao, W. & Liu, Y. J. Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases. Nat. Rev. Immunol. 8, 594\u2013606 (2008).","journal-title":"Nat. Rev. Immunol."},{"key":"1318_CR141","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1126\/science.284.5421.1835","volume":"284","author":"FP Siegal","year":"1999","unstructured":"Siegal, F. P. et al. The nature of the principal type 1 interferon-producing cells in human blood. Science 284, 1835\u20131837 (1999).","journal-title":"Science"},{"key":"1318_CR142","doi-asserted-by":"publisher","first-page":"6306","DOI":"10.4049\/jimmunol.163.11.6306","volume":"163","author":"H Vallin","year":"1999","unstructured":"Vallin, H., Perers, A., Alm, G. V. & R\u00f6nnblom, L. Anti-double-stranded DNA antibodies and immunostimulatory plasmid DNA in combination mimic the endogenous IFN-alpha inducer in systemic lupus erythematosus. J. Immunol. 163, 6306\u20136313 (1999).","journal-title":"J. Immunol."},{"key":"1318_CR143","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1002\/art.20254","volume":"50","author":"T L\u00f6vgren","year":"2004","unstructured":"L\u00f6vgren, T., Eloranta, M. L., B\u00e5ve, U., Alm, G. V. & R\u00f6nnblom, L. Induction of interferon-\u03b1 production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. Arthritis Rheum. 50, 1861\u20131872 (2004).","journal-title":"Arthritis Rheum."},{"key":"1318_CR144","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1056\/NEJMoa2118024","volume":"387","author":"VP Werth","year":"2022","unstructured":"Werth, V. P. et al. Trial of Anti-BDCA2 antibody litifilimab for cutaneous lupus erythematosus. N. Engl. J. Med. 387, 321\u2013331 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1318_CR145","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1172\/JCI124466","volume":"129","author":"R Furie","year":"2019","unstructured":"Furie, R. et al. Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus. J. Clin. Invest. 129, 1359\u20131371 (2019).","journal-title":"J. Clin. Invest."},{"key":"1318_CR146","doi-asserted-by":"publisher","first-page":"jem.20190811","DOI":"10.1084\/jem.20190811","volume":"217","author":"YL Chen","year":"2020","unstructured":"Chen, Y. L. et al. Re-evaluation of human BDCA-2+ DC during acute sterile skin inflammation. J. Exp. Med. 217, jem.20190811 (2020).","journal-title":"J. Exp. Med."},{"key":"1318_CR147","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/1523-1747.ep12500069","volume":"79","author":"RD Sontheimer","year":"1982","unstructured":"Sontheimer, R. D. & Bergstresser, P. R. Epidermal Langerhans cell involvement in cutaneous lupus erythematosus. J. Invest. Dermatol. 79, 237\u2013243 (1982).","journal-title":"J. Invest. Dermatol."},{"key":"1318_CR148","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nrrheum.2013.147","volume":"9","author":"A Perl","year":"2013","unstructured":"Perl, A. Oxidative stress in the pathology and treatment of systemic lupus erythematosus. Nat. Rev. Rheumatol. 9, 674\u2013686 (2013).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1318_CR149","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adp4447","volume":"17","author":"W Li","year":"2025","unstructured":"Li, W. et al. Gluconolactone restores immune regulation and alleviates skin inflammation in lupus-prone mice and in patients with cutaneous lupus. Sci. Transl. Med. 17, eadp4447 (2025).","journal-title":"Sci. Transl. Med."},{"key":"1318_CR150","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.jpeds.2011.03.054","volume":"159","author":"J Hong","year":"2011","unstructured":"Hong, J. & Cordoro, K. M. Discoid lupus erythematosus in a teenager. J. Pediatr. 159, 350 (2011).","journal-title":"J. Pediatr."},{"key":"1318_CR151","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1002\/art.34473","volume":"64","author":"M Petri","year":"2012","unstructured":"Petri, M. et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 64, 2677\u20132686 (2012).","journal-title":"Arthritis Rheum."},{"key":"1318_CR152","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.775353","volume":"12","author":"L Abernathy-Close","year":"2021","unstructured":"Abernathy-Close, L. et al. B cell signatures distinguish cutaneous lupus erythematosus subtypes and the presence of systemic disease activity. Front. Immunol. 12, 775353 (2021).","journal-title":"Front. Immunol."},{"key":"1318_CR153","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.3390\/jcm8081244","volume":"8","author":"CC Berthier","year":"2019","unstructured":"Berthier, C. C. et al. Molecular profiling of cutaneous lupus lesions identifies subgroups distinct from clinical phenotypes. J. Clin. Med. 8, 1244 (2019).","journal-title":"J. Clin. Med."},{"key":"1318_CR154","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.173437","volume":"9","author":"SK Shoffner-Beck","year":"2024","unstructured":"Shoffner-Beck, S. K. et al. Lupus dermal fibroblasts are proinflammatory and exhibit a profibrotic phenotype in scarring skin disease. JCI Insight 9, e173437 (2024).","journal-title":"JCI Insight"},{"key":"1318_CR155","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.jdermsci.2013.11.007","volume":"73","author":"BF Chong","year":"2014","unstructured":"Chong, B. F. et al. Differential expression of BAFF and its receptors in discoid lupus erythematosus patients. J. Dermatol. Sci. 73, 216\u2013224 (2014).","journal-title":"J. Dermatol. Sci."},{"key":"1318_CR156","doi-asserted-by":"publisher","first-page":"2885","DOI":"10.1016\/j.jid.2022.03.033","volume":"142","author":"I Lerman","year":"2022","unstructured":"Lerman, I. et al. Prominent B-cell signature differentiates discoid from subacute cutaneous lupus erythematosus. J. Investig. Dermatol. 142, 2885\u20132895.e2882 (2022).","journal-title":"J. Investig. Dermatol."},{"key":"1318_CR157","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1136\/annrheumdis-2021-220349","volume":"80","author":"SA Jenks","year":"2021","unstructured":"Jenks, S. A. et al. B cell subset composition segments clinically and serologically distinct groups in chronic cutaneous lupus erythematosus. Ann. Rheum. Dis. 80, 1190\u20131200 (2021).","journal-title":"Ann. Rheum. Dis."},{"key":"1318_CR158","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.jid.2024.07.007","volume":"145","author":"M Ogawa-Momohara","year":"2025","unstructured":"Ogawa-Momohara, M. et al. Multiplexed mass cytometry of cutaneous lupus erythematosus and dermatomyositis skin: an in-depth, B-cell-directed immunoprofile. J. Invest. Dermatol. 145, 190\u2013193.e2 (2025).","journal-title":"J. Invest. Dermatol."},{"key":"1318_CR159","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1912196","volume":"382","author":"EF Morand","year":"2020","unstructured":"Morand, E. F. et al. Trial of anifrolumab in active systemic lupus erythematosus. N. Engl. J. Med. 382, 211\u2013221 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1318_CR160","doi-asserted-by":"publisher","first-page":"e179","DOI":"10.1016\/j.jaad.2010.06.018","volume":"65","author":"A Kuhn","year":"2011","unstructured":"Kuhn, A., Ruland, V. & Bonsmann, G. Cutaneous lupus erythematosus: update of therapeutic options part I. J. Am. Acad. Dermatol. 65, e179\u2013e193 (2011).","journal-title":"J. Am. Acad. Dermatol."},{"key":"1318_CR161","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.semarthrit.2019.07.010","volume":"50","author":"JL Fairley","year":"2020","unstructured":"Fairley, J. L., Oon, S., Saracino, A. M. & Nikpour, M. Management of cutaneous manifestations of lupus erythematosus: a systematic review. Semin. Arthritis Rheum. 50, 95\u2013127 (2020).","journal-title":"Semin. Arthritis Rheum."},{"key":"1318_CR162","doi-asserted-by":"publisher","first-page":"2880","DOI":"10.1097\/MS9.0000000000003047","volume":"87","author":"AH Alshathri","year":"2025","unstructured":"Alshathri, A. H. et al. Efficacy and safety of calcineurin inhibitors in cutaneous lupus: a systematic review and brief meta-analysis of recommended concentration, type, and outcomes. Ann. Med. Surg. 87, 2880\u20132888 (2025).","journal-title":"Ann. Med. Surg."},{"key":"1318_CR163","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1111\/j.1365-2230.2008.03138.x","volume":"34","author":"B Barikbin","year":"2009","unstructured":"Barikbin, B., Givrad, S., Yousefi, M. & Eskandari, F. Pimecrolimus 1% cream versus betamethasone 17-valerate 0.1% cream in the treatment of facial discoid lupus erythematosus: a double-blind, randomized pilot study. Clin. Exp. Dermatol. 34, 776\u2013780 (2009).","journal-title":"Clin. Exp. Dermatol."},{"key":"1318_CR164","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.jaad.2010.03.037","volume":"65","author":"A Kuhn","year":"2011","unstructured":"Kuhn, A. et al. Efficacy of tacrolimus 0.1% ointment in cutaneous lupus erythematosus: a multicenter, randomized, double-blind, vehicle-controlled trial. J. Am. Acad. Dermatol. 65, 54\u201364 (2011).","journal-title":"J. Am. Acad. Dermatol."},{"key":"1318_CR165","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1002\/jcph.537","volume":"55","author":"X Wang","year":"2015","unstructured":"Wang, X. et al. Tacrolimus 0.03% ointment in labial discoid lupus erythematosus: a randomized, controlled clinical trial. J. Clin. Pharmacol. 55, 1221\u20131228 (2015).","journal-title":"J. Clin. Pharmacol."},{"key":"1318_CR166","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14675","volume":"34","author":"DP Barua","year":"2021","unstructured":"Barua, D. P. et al. Comparison of effectiveness of topical tacrolimus 0.1% vs topical halobetasol propionate 0.05% as an add-on to oral hydroxychloroquine in discoid lupus erythematosus. Dermatol. Ther. 34, e14675 (2021).","journal-title":"Dermatol. Ther."},{"key":"1318_CR167","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.jaad.2019.07.027","volume":"82","author":"WD Shipman","year":"2020","unstructured":"Shipman, W. D., Vernice, N. A., Demetres, M. & Jorizzo, J. L. An update on the use of hydroxychloroquine in cutaneous lupus erythematosus: a systematic review. J. Am. Acad. Dermatol. 82, 709\u2013722 (2020).","journal-title":"J. Am. Acad. Dermatol."},{"key":"1318_CR168","first-page":"CD007478","volume":"3","author":"CW Hannon","year":"2021","unstructured":"Hannon, C. W., McCourt, C., Lima, H. C., Chen, S. & Bennett, C. Interventions for cutaneous disease in systemic lupus erythematosus. Cochrane Database Syst. Rev. 3, CD007478 (2021).","journal-title":"Cochrane Database Syst. Rev."},{"key":"1318_CR169","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41584-020-0372-x","volume":"16","author":"E Schrezenmeier","year":"2020","unstructured":"Schrezenmeier, E. & D\u00f6rner, T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat. Rev. Rheumatol. 16, 155\u2013166 (2020).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1318_CR170","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1001\/archdermatol.2011.191","volume":"147","author":"AY Chang","year":"2011","unstructured":"Chang, A. Y. et al. Response to antimalarial agents in cutaneous lupus erythematosus. Arch. Dermatol. 147, 1261\u20131267 (2011).","journal-title":"Arch. Dermatol."},{"key":"1318_CR171","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1042\/BST20190803","volume":"48","author":"AM Alqarni","year":"2020","unstructured":"Alqarni, A. M. & Zeidler, M. P. How does methotrexate work? Biochem. Soc. Trans. 48, 559\u2013567 (2020).","journal-title":"Biochem. Soc. Trans."},{"key":"1318_CR172","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.immuni.2023.04.001","volume":"56","author":"R Bharadwaj","year":"2023","unstructured":"Bharadwaj, R. et al. Methotrexate suppresses psoriatic skin inflammation by inhibiting muropeptide transporter SLC46A2 activity. Immunity 56, 998\u20131012.e1018 (2023).","journal-title":"Immunity"},{"key":"1318_CR173","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s40257-024-00916-6","volume":"26","author":"S Pazhyanur","year":"2025","unstructured":"Pazhyanur, S. et al. Characterization of clinicopathological features and autoantibody profiles in patients with cutaneous lupus erythematous: a single-center retrospective study. Am. J. Clin. Dermatol. 26, 265\u2013273 (2025).","journal-title":"Am. J. Clin. Dermatol."},{"key":"1318_CR174","doi-asserted-by":"publisher","first-page":"e101","DOI":"10.1016\/S2665-9913(20)30342-8","volume":"3","author":"IN Bruce","year":"2021","unstructured":"Bruce, I. N. et al. Pharmacokinetics, pharmacodynamics, and safety of subcutaneous anifrolumab in patients with systemic lupus erythematosus, active skin disease, and high type I interferon gene signature: a multicentre, randomised, double-blind, placebo-controlled, phase 2 study. Lancet Rheumatol. 3, e101\u2013e110 (2021).","journal-title":"Lancet Rheumatol."},{"key":"1318_CR175","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1002\/acr.25058","volume":"75","author":"R Kneeland","year":"2023","unstructured":"Kneeland, R. et al. Improvement in cutaneous lupus erythematosus after twenty weeks of belimumab use: a systematic review and meta-analysis. Arthritis Care Res. 75, 1838\u20131848 (2023).","journal-title":"Arthritis Care Res."},{"key":"1318_CR176","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2024.103723","volume":"24","author":"LA Bokor","year":"2025","unstructured":"Bokor, L. A. et al. Deucravacitinib shows superior efficacy and safety in cutaneous lupus erythematosus compared to various biologics and small molecules \u2014 a systematic review and meta-analysis. Autoimmun. Rev. 24, 103723 (2025).","journal-title":"Autoimmun. Rev."},{"key":"1318_CR177","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.2025-0390.O010","volume":"52","author":"D Pearson","year":"2025","unstructured":"Pearson, D. et al. Randomized, placebo-controlled phase II study of enpatoran, a small molecule toll-like receptor 7\/8 inhibitor, in cutaneous lupus erythematosus: results from Cohort A. J. Rheumatol. 52 (Suppl. 1), 11 (2025).","journal-title":"J. Rheumatol."},{"key":"1318_CR178","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1093\/rheumatology\/keab685","volume":"61","author":"VP Werth","year":"2022","unstructured":"Werth, V. P. et al. Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study. Rheumatology 61, 2413\u20132423 (2022).","journal-title":"Rheumatology"},{"key":"1318_CR179","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1001\/jamadermatol.2021.5485","volume":"158","author":"G Sprow","year":"2022","unstructured":"Sprow, G., Afarideh, M. & Werth, V. P. Interventions for cutaneous disease in systemic lupus erythematosus: summary of a cochrane review. JAMA Dermatol. 158, 200\u2013201 (2022).","journal-title":"JAMA Dermatol."},{"key":"1318_CR180","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/S0140-6736(22)02607-1","volume":"401","author":"EF Morand","year":"2023","unstructured":"Morand, E. F. et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I). Lancet 401, 1001\u20131010 (2023).","journal-title":"Lancet"},{"key":"1318_CR181","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/S0140-6736(22)02546-6","volume":"401","author":"M Petri","year":"2023","unstructured":"Petri, M. et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II). Lancet 401, 1011\u20131019 (2023).","journal-title":"Lancet"},{"key":"1318_CR182","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1001\/jamadermatol.2018.5077","volume":"155","author":"N Zimmermann","year":"2019","unstructured":"Zimmermann, N. et al. Assessment of clinical response to Janus kinase inhibition in patients with familial chilblain lupus and TREX1 mutation. JAMA Dermatol. 155, 342\u2013346 (2019).","journal-title":"JAMA Dermatol."},{"key":"1318_CR183","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","volume":"28","author":"A Mackensen","year":"2022","unstructured":"Mackensen, A. et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat. Med. 28, 2124\u20132132 (2022).","journal-title":"Nat. Med."},{"key":"1318_CR184","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","volume":"390","author":"F M\u00fcller","year":"2024","unstructured":"M\u00fcller, F. et al. CD19 CAR T-cell therapy in autoimmune disease \u2014 a case series with follow-up. N. Engl. J. Med. 390, 687\u2013700 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1318_CR185","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1056\/NEJMc2408786","volume":"391","author":"M Hagen","year":"2024","unstructured":"Hagen, M. et al. BCMA-targeted T-cell-engager therapy for autoimmune disease. N. Engl. J. Med. 391, 867\u2013869 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1318_CR186","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1002\/art.30087","volume":"63","author":"Z Liu","year":"2011","unstructured":"Liu, Z. et al. Interferon-\u03b1 accelerates murine systemic lupus erythematosus in a T cell-dependent manner. Arthritis Rheum. 63, 219\u2013229 (2011).","journal-title":"Arthritis Rheum."},{"key":"1318_CR187","doi-asserted-by":"publisher","first-page":"306","DOI":"10.3389\/fimmu.2013.00306","volume":"4","author":"Z Liu","year":"2013","unstructured":"Liu, Z. & Davidson, A. IFN\u03b1 inducible models of murine SLE. Front. Immunol. 4, 306 (2013).","journal-title":"Front. Immunol."},{"key":"1318_CR188","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jaut.2015.08.005","volume":"65","author":"KL Clark","year":"2015","unstructured":"Clark, K. L. et al. Epidermal injury promotes nephritis flare in lupus-prone mice. J. Autoimmun. 65, 38\u201348 (2015).","journal-title":"J. Autoimmun."},{"key":"1318_CR189","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.jaad.2025.02.066","volume":"93","author":"D Bar","year":"2025","unstructured":"Bar, D. et al. Early initiation of hydroxychloroquine in cutaneous lupus erythematosus to prevent progression to systemic lupus erythematosus: a long-term follow-up study. J. Am. Acad. Dermatol. 93, 55\u201363 (2025).","journal-title":"J. Am. Acad. Dermatol."},{"key":"1318_CR190","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s40257-023-00774-8","volume":"24","author":"D Niebel","year":"2023","unstructured":"Niebel, D., de Vos, L., Fetter, T., Br\u00e4gelmann, C. & Wenzel, J. Cutaneous lupus erythematosus: an update on pathogenesis and future therapeutic directions. Am. J. Clin. Dermatol. 24, 521\u2013540 (2023).","journal-title":"Am. J. Clin. Dermatol."},{"key":"1318_CR191","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2025.04.033","author":"JR Gehlhausen","year":"2025","unstructured":"Gehlhausen, J. R. et al. Cutaneous lupus features specialized stromal niches and altered retroelement expression. J. Invest. Dermatol. https:\/\/doi.org\/10.1016\/j.jid.2025.04.033 (2025).","journal-title":"J. Invest. Dermatol."},{"key":"1318_CR192","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/jdv.14053","volume":"31","author":"A Kuhn","year":"2017","unstructured":"Kuhn, A. et al. S2k guideline for treatment of cutaneous lupus erythematosus \u2014 guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV). J. Eur. Acad. Dermatol. Venereol. 31, 389\u2013404 (2017).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"1318_CR193","first-page":"1236","volume":"19","author":"M Worm","year":"2021","unstructured":"Worm, M. et al. S2k guideline: diagnosis and management of cutaneous lupus erythematosus \u2014 Part 1: classification, diagnosis, prevention, activity scores. J. Dtsch. Dermatol. Ges. 19, 1236\u20131247 (2021).","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"1318_CR194","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/ard-2023-224762","volume":"83","author":"A Fanouriakis","year":"2024","unstructured":"Fanouriakis, A. et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann. Rheum. Dis. 83, 15\u201329 (2024).","journal-title":"Ann. Rheum. Dis."},{"key":"1318_CR195","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2021.102707","volume":"123","author":"Q Lu","year":"2021","unstructured":"Lu, Q. et al. Guideline for the diagnosis, treatment and long-term management of cutaneous lupus erythematosus. J. Autoimmun. 123, 102707 (2021).","journal-title":"J. Autoimmun."},{"key":"1318_CR196","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.jdcr.2023.09.013","volume":"41","author":"J Kleitsch","year":"2023","unstructured":"Kleitsch, J., Lim, D., Pandya, R. & Werth, V. P. Subacute cutaneous lupus erythematosus versus discoid lupus erythematosus: a challenging diagnosis. JAAD Case Rep. 41, 93\u201397 (2023).","journal-title":"JAAD Case Rep."},{"key":"1318_CR197","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.915828","volume":"9","author":"T Fetter","year":"2022","unstructured":"Fetter, T., Braegelmann, C., de Vos, L. & Wenzel, J. Current concepts on pathogenic mechanisms and histopathology in cutaneous lupus erythematosus. Front. Med. 9, 915828 (2022).","journal-title":"Front. Med."},{"key":"1318_CR198","doi-asserted-by":"publisher","first-page":"S69","DOI":"10.1016\/j.jisp.2016.09.001","volume":"18","author":"JC O\u2019Brien","year":"2017","unstructured":"O\u2019Brien, J. C. & Chong, B. F. Not just skin deep: systemic disease involvement in patients with cutaneous lupus. J. Investig. Dermatol. Symp. Proc. 18, S69\u2013S74 (2017).","journal-title":"J. Investig. Dermatol. Symp. Proc."},{"key":"1318_CR199","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1111\/j.0022-202X.2005.23889.x","volume":"125","author":"J Albrecht","year":"2005","unstructured":"Albrecht, J. et al. The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus. J. Investig. Dermatol. 125, 889\u2013894 (2005).","journal-title":"J. Investig. Dermatol."},{"key":"1318_CR200","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2025.08.012","author":"S Chambers","year":"2025","unstructured":"Chambers, S. et al. Pain and itch in cutaneous lupus erythematosus. J. Am. Acad. Dermatol. https:\/\/doi.org\/10.1016\/j.jaad.2025.08.012 (2025).","journal-title":"J. Am. Acad. Dermatol."},{"key":"1318_CR201","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1177\/09612033211016098","volume":"30","author":"D Samotij","year":"2021","unstructured":"Samotij, D. et al. Clinical characteristics of itch in cutaneous lupus erythematosus: a prospective, multicenter, multinational, cross-sectional study. Lupus 30, 1385\u20131393 (2021).","journal-title":"Lupus"},{"key":"1318_CR202","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/3491798","volume":"2018","author":"D Samotij","year":"2018","unstructured":"Samotij, D. et al. Prevalence of pruritus in cutaneous lupus erythematosus: brief report of a multicenter, multinational cross-sectional study. Biomed. Res. Int. 2018, 3491798 (2018).","journal-title":"Biomed. Res. Int."}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41584-025-01318-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-025-01318-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-025-01318-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T01:02:17Z","timestamp":1763686937000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41584-025-01318-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,7]]},"references-count":202,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1318"],"URL":"https:\/\/doi.org\/10.1038\/s41584-025-01318-6","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,7]]},"assertion":[{"value":"6 October 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.M.K. has served on advisory boards for AstraZeneca, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, EMD serrano, Exo Therapeutics, Gilead, GlaxoSmithKline, Integer Bio, Aurinia Pharmaceuticals, Rome Therapeutics, Synthekine, Vivideon, Novartis and Ventus Therapeutics. She has received grant support from Rome Therapeutics, Ventus Therapeutics, Janssen and Bristol Myers Squibb. B.K., A.C.B. and L.A.-C. declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}